The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer

Summary

A clinical study of WJ01024 in subjects with advanced cancer in China, to evaluate the safety, tolerability, PK and efficacy of WJ01024. This study includes a dose escalation part and a dose expansion part. Patients receive WJ01024 on Day 1 and Day 3 of each week, 4 weeks as a cycle, until disease progression, or intolerable toxicity , withdrawal of consent, or end of the study, whichever occurs first.

Timeline

Start

2021-09-10

Primary completion

2025-05-28

Completion

2025-05-28

Outcome

Outcome not reported

Stopped (Business): “Due to a change in the development strategy, the sponsor decided to terminate the study on May 28, 2025”

Drugs

Indications